Maravai LifeSciences Holdings (MRVI) has wrapped up FY 2025 with fourth quarter revenue of US$49.9 million and a basic EPS loss of US$0.25, set against a trailing twelve month loss of US$0.91 per share on revenue of US$185.7 million. Over recent quarters the company has seen revenue move from US$56.4 million in Q4 2024 to US$41.6 million in Q3 2025 and then to US$49.9 million in Q4 2025. Quarterly basic EPS has ranged from a loss of US$0.19 in Q4 2024 to losses between US$0.18 and US$0.27 through FY 2025, leaving investors focused on how quickly margins can stabilize and whether the current loss profile can narrow from here.

See our full analysis for Maravai LifeSciences Holdings.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the widely followed narratives around Maravai's growth potential, risk profile, and path toward better margins.

TTM loss of US$130.8 million keeps profitability in focus

• Over the last twelve months, Maravai booked revenue of US$185.7 million and a net loss of US$130.8 million, which works out to a basic EPS loss of US$0.91.
• Bears argue that a five year pattern of losses growing at about 56.2% a year points to a business model under pressure, and the recent quarterly losses give them support:
  • FY 2025 quarterly net losses ranged from US$25.6 million to US$39.6 million on quarterly revenue between US$41.6 million and US$49.9 million, which fits with the view that margins are still heavily negative.
  • With forecasts indicating Maravai is expected to remain unprofitable over the next three years, critics highlight that there is no earnings track record yet to counter the concern about persistent loss making operations.

Maravai's recent track record of widening losses is exactly what skeptics flag as a core risk, and they lean on that history when questioning how durable any margin recovery might be. 🐻 Maravai LifeSciences Holdings Bear Case

8.1% revenue growth trails 10.4% US market pace

• The trailing revenue growth rate of 8.1% a year is below the cited US market rate of 10.4% a year, even though Maravai generated US$185.7 million in revenue over the last twelve months.
• Supporters of the bullish view think cost actions and product expansion can still make that level of growth attractive, and the current figures partly frame that debate:
  • Management initiatives targeting more than US$50 million in annualized cost savings are being weighed against FY 2025 losses of US$130.8 million over the last twelve months, so bulls point to the gap as room for improvement while bears see it as a sign of heavy expense.
  • Bullish analysts also talk about growth from areas like biologics safety testing and mRNA related consumables, and the 8.1% revenue growth rate is a concrete data point investors can use to compare those expectations with what the business has actually delivered over the past year.

If you want to see how optimistic investors connect these growth figures to their Maravai thesis, the bullish case in particular is worth a look. 🐂 Maravai LifeSciences Holdings Bull Case

P/S of 2.8x and DCF fair value of US$7.10 vs price of US$3.56

• Maravai trades at a P/S of 2.8x compared with 3.0x for the wider US Life Sciences group and 6.5x for peers, and against a stated DCF fair value of US$7.10 the current share price of US$3.56 sits materially lower.
• Consensus narrative points out a tension between low multiples and ongoing losses, and the current numbers show why the valuation debate is so active:
  • The trailing twelve month loss of US$130.8 million and EPS loss of US$0.91 mean common P/E based checks are not usable, so investors are leaning more on revenue based multiples like P/S and model based estimates such as the DCF fair value of US$7.10.
  • With a consensus analyst price target of US$4.07 and the DCF fair value above that at US$7.10, some investors will see room between the US$3.56 share price and these reference points, while others may view the discount as compensation for the unprofitable status highlighted in the loss and EPS figures.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Maravai LifeSciences Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mixed tone of this update leaves you split, that is a good cue to move fast and check the details yourself so you are not relying on headlines alone. You can also see what has investors optimistic by looking at our breakdown of 1 key reward for the company.

Explore Alternatives

Maravai is still posting heavy losses on US$185.7 million of revenue, with margins deeply negative and growth trailing the wider US market pace.

If that loss profile and volatility worry you, now may be a good time to check out 80 resilient stocks with low risk scores, so you can focus on steadier companies with more resilient fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.